Computer screens of endless strings of four-lettered DNA can be translated to twenty-lettered proteins, but other as yet unknown translations will be necessary to convert this alphabetical soup to biology [1] .
This review is addressed to clinical nephrologists with the aim of clarifying the breakthroughs that genetics may make in the understanding of essential hypertension. We summarize some of the research performed in genetic animal models of hypertension as well as in human hypertension, and compare the rat with the human data in an attempt to draw some general conclusions. A summary of the modern genetic strategies is provided that may be used to identify the genes responsible for essential hypertension, together with an explanation of the genetic terminology the nonspecialist reader may find in dealing with the genetics of complex diseases (and specifically hypertension).
Simple genetic diseases are not that simple, and hypertension is far more complex
Though remarkable progress has been made in human genetics, it is becoming clearer each day that even the simplest genetic trait, that is, one caused by a monogenic disease, exhibits a bewildering complexity [2] . Just as examples, three prototype diseases are briefly described.
(1) Phenylketonuria, an inherited disease associated with severe mental retardation, is caused by a defect in the gene coding for phenylalanine hydroxylase. However, the enzyme deficiency is not enough to cause the disease. Exposure to dietary phenylalanine is also required. In fact, mental retardation does not occur if either factor (diet and abnormal enzyme) is missing [3] . Thus, an interaction with the appropriate environment is crucial for presentation of the phenotype. (2) Over 400 mutations of the cystic fibrosis gene have been described [4] , and while some are benign and of no clinical relevance, others cause more or less severe forms of the disease. This means that not all the mutations in the gene cause the disease and that different mutations in the same gene may cause a different severity of the disease. (3) Hereditary spastic paraplegia in its autosomal dominant form is a clinically homogeneous, inherited degenerative disorder of the motor system, but is genetically heterogeneous because in different families the disease-causing locus is attributed to different chromosomes, some still not identified. This suggests that there is a common pathway on which the different abnormal gene products must act. Any interruption of such a pathway by any of such defective genes may cause the same phenotypic expression of the disease [5] .
More than 40 years of epidemiological studies have identified different environmental concomitants associated with the development of essential hypertension, and analysis of blood pressure in families has demonstrated that a substantial proportion of blood pressure variation among individuals is determined by genetic factors. There is no agreement on the proportion of blood pressure variability explained by genetic factors, but the general estimate is around 30 to 40%. However, simple biometric calculations by Cavalli Sforza and Bodmer demonstrated that it may be as much as 70 to 80%, about 40% of it due to dominance effect, which should indicate the existence of some major gene effect over a polygenic background [6] . While much is understood about environmental factors, the genetic factors are still largely unknown. On the other hand, genetics (and molecular biology) permit the detection of the primary pathogenetic mechanisms of diseases by identification of the specific DNA segment that carries the pathogenic mutation, which should eventually allow reconstruction of the entire sequence of events from DNA mutation to the disease.
The classical approach in a search for the pathogenetic mechanism of a disease is to go from the top of complexity, at the whole organism level, down to the DNA level by dissecting the disease phenotype into several intermediate phenotypes at the different levels of biological organization [7] . This top down approach (from the complexity of the phenotype to the simple DNA sequence alteration) has been fruitful, as it has led to the discovery of many genes that cause rare monogenic disorders. The situation is considerably more complicated in the case of common, complex diseases such as essential hypertension for several reasons.
(
1) Hypertension is caused by many genes with locus heterogeneity or inheritance that is polygenic or oligogenic.
While there is general agreement that essential hypertension is caused by many genes, two alternatives are possible. Different forms of essential hypertension share only the same final phenotype but have different pathogenetic mechanisms. In this case only any one of the many possible mutated genes is needed to express the disease, as in the case of monogenic forms of hypertension [8] . Alternatively, more than one gene with at least one deleterious allele must be simultaneously present in an individual to cause essential hypertension. In the first case we are dealing with locus heterogeneity, in the second with polygenic or oligogenic inheritance. Both alternatives may be true for essential hypertension, although it is highly likely that it is polygenic and heterogeneous. In other words, the phenotype is determined by allelic variation at more than one gene at a time. Moreover, different sets of allelic variation of different genes may cause a similar final phenotype. To further complicate the picture, multigenic inheritance may be additive or epistatic.
(2) Environmental factors. The environment can alter the sequence of events that lead from the primary DNA mutation to the final phenotype, and act at all the different levels of biological organization.
(3) Compensatory factors. No biological function operates in a closed system, so any malfunctioning protein may influence (by inducing or inhibiting) transcription of other proteins, which in their turn may have an effect on the final phenotype, so that the pathogenic mutation of any gene may be obscured by the redundancy of compensatory mechanisms and the disease phenotype may be determined only by compensatory overexpression or inhibition of another gene, whose DNA sequence is indeed normal.
Though the complexity of the picture may appear discouraging due to the large number of potential candidate genes and possible confounding interactions, among the many physiological and/or biochemical mechanisms that affect blood pressure only a relatively few are involved in its long-term control [9] . Whatever the initiating event, some alteration in kidney function must occur to produce a permanent blood pressure increase. Guyton called this phenomenon the "overriding role of the kidney on blood pressure control" [9] . Recent findings on the genetics of essential hypertension seem to support this notion. Among the few loci or genes associated with blood pressure regulation in humans or rats found thus far, most are directly or indirectly involved in the renal control of sodium balance [8] . Of course, this does not exclude the possibility that other genetic defects operating through non-renal mechanisms may be discovered in the future, but it underlines the importance of the renal genetic-molecular mechanisms of essential hypertension. This importance is also supported by the overwhelming amount of data, collected over a period of more than 30 years, that deal with the crucial interaction between body sodium and renin in determining the final level of blood pressure and kidney function. Careful studies of sodium handling by the kidney, the renin-angiotensin system, the pressor response to sodium load or depletion, or to other aspects of renal function under different experimental conditions may help to cluster hypertensive patients into discrete subgroups whose members should should all have the same, more clearly identifiable renal genetic-molecular mechanisms [10] . This consideration underlines the crucial role that the clinical and experimental nephrologist may play in clarifying the pathogenetic mechanisms of essential hypertension.
STRATEGIES FOR IDENTIFYING THE GENETIC MECHANISMS OF ESSENTIAL HYPERTENSION

How to search and what to search for
When two alleles of two different genes are located in close proximity on the same chromosome, there is only a small chance that recombination will occur between them and thay are said to be in linkage dysequilibrium (or to be associated). The position of a gene on a chromosome is called its "locus." In modern terminology a locus comprises not only genes but also genetic units without a known function. The concept of linkage dysequilibrium can also be applied to phenotypes. When two phenotypes occur together in the same individual more often than expected by chance, as for the type A blood group and cancer of the stomach [11], they are said to be associated or to be in linkage dysequilibrium. One of several possibilities is tight linkage of the two genes that determine the two associated phenotypes. Taken in its broadest sense, the term linkage dysequilibrium is now currently employed to indicate that a certain locus is associated with a certain disease [reviewed in 12]. When used in this way, it indicates that the occurrence of a particular genotype for a locus occurs more often than expected when the disease under investigation is present. This only signifies that the locus is of interest, that is, that a gene possibly involved in the pathogenesis of the disease is located in proximity to the identified locus, whereas the observed genotype is only a "genetic" marker of the disease but does not allow any speculation on which is the gene that determines the disease. A genetic marker is thus any identifiable DNA segment that may be in linkage dysequilibrium with the disease of interest. A marker can be a particular variant or allele of any DNA segment or gene that is in tight linkage with the disease allele. Currently the most used DNA markers are anonymous polymorphic DNA markers that are widely and homogeneously distributed across the whole genome. They are derived from repetitive sequence elements based either on short (microsatellite) or longer (minisatellite) domains that are repeated in tandem. There are numerous possible alleles for such markers (up to 30 to 40), which are thus highly polymorphic. Such a large number of alleles has a practical utility for geneticists, as they provide the possibility of observing transmission of the marker with that of the phenotype under investigation.
Two conceptually different approaches may be employed in the study of genetic determinants of essential hypertension. The first is the candidate gene approach, which takes advantage of polymorphism in genes that encode proteins of known or suspected importance in blood pressure regulation. The cosegregation with blood pressure of a candidate gene variant or of an allele of any kind of DNA marker (allele of any known gene, RFLP, mini-or microsatellite) mapping within or very close to the candidate gene is considered good evidence for a pathogenic role of the gene under investigation, particularly when functional alteration of the candidate gene function is also demonstrated. The second approach, random genome scanning, also may use anonymous polymorphic DNA markers as well as known variants of known genes, but it tests many markers in the same population without previous assumptions on which is or where is the disease gene. An identified genetic locus influencing a quantitative trait such as blood pressure is called quantitative trait locus (QTL) [13] . It is important to remember that when blood pressure QTLs are being sought by genome scanning, a very large number of loci are evaluated in the same experimental unit. To avoid numerous false positives, such experiments should set a significance level in the range of P Ͻ 10 Ϫ5 [14], although there is no general consensus on such stringent criteria.
At present no agreement exists as to the most suitable kind of sample to study and genetic strategy to adopt in order to identify the genes that cause essential hypertension. Two distinct general strategies are available: linkage analysis and association analysis. Each one has specific advantages and drawbacks. Both linkage and association methodologies are powerful and useful to detect and map genes potentially responsible for many human disorders. There are major differences in the particular "material" used as linkage analyses are applied to families and associations to the general population. Although linkage studies are powerful methods for detecting disease loci, they depend heavily on the a priori hypothesis that a single major locus is responsible for susceptibility to the disease and, moreover, they are sensitive to errors in parameters used in the genetic model, unless nonparametric approaches are used. On the other hand, as essential hypertension is a multifactorial disease, the genetic association strategy has the advantage of being able to detect not only major gene effects but also minor ones, which may not be revealed by linkage analyses. A conspicuous drawback of association analysis is that it is much more sensitive to increases in genetic distance of the marker from the disease locus, making it more suitable to test candidate genes than to perform a complete genome scan, which would require an immensely large (and dense) number of markers [15] . Furthermore, particularly in the case of essential hypertension, precise definition of the control sample is critical. This is the weakest point of any association study, as the gross phenotypic definition of "healthy" or "not affected" may not be precise enough due to the heterogenous polymorphic etiology of a complex, multifactorial trait.
Genetic analysis of essential hypertension, as that of any other complex disease, suffers from three fundamental complications.
(1) Each gene may have only a small quantitative effect on the disorder. This implies that the relative risk for the genotype, that is, the increased chance that an individual with a particular genotype for a particular allele has the disease, is small and that a substantial number of nonaffected individuals can be found with the genotype of the affected ones. Risch and Merikangas recently considered this problem in detail and concluded that linkage analysis has only a limited power to detect genes of modest effect such as those that are implicated in the pathogenesis of essential hypertension. Their argument is that, for alleles occurring with a relatively high frequency in the population and yet confer a relatively small genotype risk, linkage analysis provides few chances to identify disease loci because the number of families required, several hundreds to thousands, is currently far beyond anyone's ability [16] .
(2) It is likely that essential hypertension is genetically heterogeneous. However, all linkage methods focus on a single locus at one time in the expectation (hope) that if that locus "accounts for a high enough proportion of cases it can be detected" [17] . Statistical tests for heterogeneity should thus be used before rejecting the hypothesis of linkage for a candidate gene.
(3) Epistasis is very likely to be present in essential hypertension. Frankel and Schork have recently discussed two examples of epistatic interaction in determining cancer susceptibility in mice [18] . In both cases, there was evidence for a two-locus system in which neither locus had an effect per se, and neither would be detectable with standard linkage designs [19, 20] .
Monogenic forms of human hypertension
Monogenic forms of human hypertension are very rare syndromes in which mutations in single genes are sufficient to produce large blood pressure changes. Although this review is concerned with essential hypertension, a brief description of monogenic forms of hypertension is included, as knowledge of these forms may provide new insights into blood pressure regulation. A recent review on this topic is in [8] .
Liddle's syndrome. Liddle's syndrome is an autosomal dominant form of salt-sensitive hypertension characterized by early onset, hypokalemia, and low renin and aldosterone levels. It can be treated by salt restriction and amiloride (the selective inhibitor of the epithelial Na channel). A linkage study in Liddle's original pedigree demonstrated linkage to a segment of chromosome 16 containing two genes, the ␤ and ␥ subunits of the epithelial Na channel, which were considered plausible candidates because sodium reabsorption through this channel is one of the major determinants of tubular sodium reabsorption [21] . Different mutations causing truncation of the cytoplasmic Cterminus of the ␤ or ␥ subunit have subsequently been described as responsible for Liddle's syndrome in different pedigrees [22] [23] [24] . In all cases, premature truncation of the cytoplasmic C-terminus of either the ␤ or ␥ subunit results in constitutive activation of the channel (that is, loss of normal negative regulation of the channel, and hence increased net renal sodium reabsorption). The critical role of the epithelial Na channel in maintaining salt and extracellular fluid balance and controlling blood pressure is confirmed by the finding of different mutations in both the ␣ or ␤ subunits, either of which cause pseudohypoaldosteronism type I, a rare autosomal recessive disease characterized by neonatal salt wasting, low blood pressure, hyperkalemia and metabolic acidosis. Sodium is lost as the mutations cause a striking decrease in the opening time of the Na channel (and hence of the sodium reabsorbed) [25] .
Pseudohypoaldosteronism type II or Gordon's syndrome. This is another rare form of dominant familial hypertension with low renin, high serum K, normal glomerular filtration rate and good response to salt restriction and/or thiazide diuretic treatment. Linkage analysis demonstrated locus heterogeneity, with in some families significant linkage to chromosome 17q21 [26] , which is syntenic with a segment of rat chromosome 10 that contains at least one or two blood pressure QTLs (see below).
Apparent mineralocorticoid excess. Apparant mineralocorticoid excess (AME) is an autosomal recessive form of hypertension, phenotypically similar to Liddle's syndrome (low renin and low aldosterone levels) but responsive to mineralocorticoid (type 1) receptor inhibition by spironolactone. Different mutations in the gene of the 11␤-hydroxysteroid dehydrogenase kidney isozyme cause different degrees of loss of function of the enzyme. The kidney isozyme of 11␤-hydroxysteroid dehydrogenase is expressed in distal and cortical collecting tubules, where the mineralocorticoid receptor is also present. It converts cortisol to cortisone, which has no mineralocorticoid activity, at the pre-receptor level. When the enzymatic activity is defective, normal circulating cortisol can thus produce a large mineralocorticoid effect by direct stimulation of the mineralocorticoid receptor [27, 28] . Due to the enzyme defect, affected patients have an elevated urinary tetrahydrocortisol ϩ allo-tetrahydrocortisol to tetrahydrocortisone ratio. Recently, a heterozygous hypertensive father of an affected homozygous proband has been described in a Brazilian kindred [29] . The interest of this case is that the father, who also has an altered urinary steroid ratio, had previously been defined as having essential hypertension, although with low renin and aldosterone levels and a suboptimal response to conventional antihypertensive treatment (diuretics ϩ ␤-blockers). As the urinary steroid ratio has also been reported as abnormal in some essential hypertensive individuals [30] , it is possible that subtle defects in 11␤-hydroxysteroid dehydrogenase activity also play a role in essential hypertension.
Glucocorticoid remediable aldosteronism. Glucocorticoid remediable aldosteronism (GRA) is an autosomal dominant form of hypertension with low renin but high aldosterone levels, whose secretion is controlled by ACTH and not by angiotensin II. The disease is caused by unequal crossing-over of chromosome 8 between the aldosterone synthase and 11␤-hydroxylase genes, which are tightly linked. The crossing-over produces a novel chimeric gene, which contains the proximal (regulatory) sequence of 11␤-hydroxylase and the distal (coding) sequence of aldosterone synthase. In this way the chimeric gene is under the control of ACTH but its gene product has aldosterone synthase activity [31, 32] .
The rat as a reductionist model for human hypertension
For a long time research on the pathogenetic mechanisms of hypertension focused only on the search for biochemical/physiological differences between hypertensive and normotensive humans or between spontaneously hypertensive rats and their respective normotensive control strains. Many differences were found and many biochemical/physiological mechanisms for hypertension have been proposed. Probably much of that work did not yield meaningful conclusions because, in the case of humans, the population of hypertensives is too heterogeneous and, in the case of rats, many of the observed differences between hypertensive and control strains were simply due to chance selection and fixation of specific biochemical/physiological traits rather than real causal differences relevant to the pathogenesis of hypertension. Modern genetic strategies are thus based on the search for QTLs, that is, not for the disease gene itself but for an indication of its approximate location. Unfortunately, the relative proximity of a QTL to the disease gene may mean up to 50 to 100 genes.
Rapp has proposed a series of fixed rules (a paradigm) to test whether a given trait may be important in explaining a blood pressure difference between cases and controls: (1) the trait must be different in hypertensives and normotensives; (2) it must follow the Mendelian inheritance pattern; (3) the genes that affect the trait must cosegregate with significant blood pressure differences; and (4) it must be possible to show some logical biochemical or physiological link between the identified trait and blood pressure [33, 34] . A fifth corollary rule could be the confirmation that the same kind of association between the trait (or gene malfunction that causes the specific trait or linkage with a corresponding syntenic DNA segment) and hypertension is present in some rat genetic models and in humans. As the human and rat diverged about 80 million years ago [35] , there is little chance that the trait that cosegregates with hypertension is caused by the same mutation in the same gene. The alternative possibility of a different mutation in the same gene or a mutation in another gene whose function is also needed to determine the trait must be considered as well.
Genetically hypertensive rat strains should provide a simplified experimental approach as the mechanisms responsible for hypertension seem different in each rat strain. All hypertensive rat strains were selected from different standard laboratory stock colonies by mating the offspring of a couple according to their blood pressure values (mating of offspring with higher blood pressure values originated the hypertensive strain and mating of offspring with lower blood pressure values originated the normotensive "control" strain) until the character was fixed, that is, when the hypertensive and control strain reached different stable blood pressure values. This occurs after at least 21 generations of brother-sister mating. Such an approach has a major limitation: only blood pressure is measured during the selection, and the overall genetic background that is also fixed in the strain during the selection contributes to the final blood pressure. To complicate the picture, it may happen that alleles tending to increase blood pressure in the normotensive strain and/or alleles tending to decrease blood pressure in the hypertensive one also may eventually be fixed. Moreover, during the process of fixation, other genetic differences unrelated to hypertension may be fixed as well. Due to such random fixation of different genotypes for alleles unrelated to blood pressure control, the finding of a genetic difference between the affected and the unaffected strain can by no means be taken as evidence that such a genetic difference is related to hypertension. One way to overcome the problem of chance fixation is by studying segregating populations. In this kind of experimental approach the hypertensive and control strain are crossed in order to ascertain if a particular genotype or intermediate phenotype segregates with higher or lower blood pressure levels.
One hypertensive parent and one normotensive mate to produce a first generation (F1) of hybrid offspring, which then mate to produce F2 offspring (F1 x F1) . By definition, all F1 animals will be heterozygous for all the genes which are different in the parental strains, and a complete mix-up of the genes will be obtained in the F2. It is then possible to test whether the F2 animals with higher blood pressure values differ from those with lower blood pressure values in any specific biochemical/physiological trait, candidate locus or particular allele. The demonstration of a relationship between a given locus and blood pressure indicates that one gene present in the DNA segment around the locus is a potential candidate for blood pressure control. As this segment may contain a large number of genes, additional genetic, physiological and/or biochemical studies are needed to establish which gene is the one most likely to be responsible. A major drawback of experiments performed in F2 segregating populations lies in the uniqueness of the individual animals, so that it is practically impossible to extensively characterize the animals for the intermediate phenotypes of interest.
Recombinant inbred and congenic strains provide a powerful alternative to segregating F2 populations for localizing and identifying candidate genes. They are permanent strains which can then be extensively characterized also for all intermediate phenotypes in different genetic backgrounds [36, 13] . Recombinant inbred strains are produced by random mating of pairs of F2 animals, followed by mating of the offspring of each couple for at least 20 generations to fix the characters again. Genetic analysis is then performed by testing if hypertension is inherited with the genotype of the affected original strain. Once a chromosomal region associated with hypertension in an F2 or recombinant strain has been found, congenic strains are produced by back-crossing an F1 possessing the chromosomal region of interest from the hypertensive strain with the control strain (obviously the reverse possibility of transferring the "normotensive" segment of DNA into a hypertensive genome is possible as well). This procedure is performed for several generations, and the length of the transferred DNA segment is checked with appropriate DNA markers mapping at known distances until the congenic animals are identical to the parental strain with which they are back-crossed, except for the DNA segment of interest. Many variants of this technique are available. It is possible simultaneously to select for more than one DNA segment as well against one or more other DNA segments with appropriate genotyping before mating. This technique achieves a real DNA transfer (transplant) from a hypertensive strain in a normotensive genome and may provide definitive evidence that the transferred DNA segment contains at least one gene that affects blood pressure. If the phenotype of the congenic strain differs from that of the recipient progenitor strain, this proves the existence of a locus affecting that phenotype in the transferred chromosomal segment.
Many QTLs have been found in the different genetic hypertensive rat strains. As some happen to be on the same chromosome they are presented by chromosome rather than by candidate gene in Table 1 .
Genetic manipulation provides a powerful tool for biochemical physiological studies
Modern molecular biology techniques can be used to create strains of transgenic animals, which are a powerful experimental tool to test specific hypotheses on candidate genes of essential hypertension. In a transgenic animal a foreign DNA segment (not necessarily of the same species) is introduced artificially in such a way that it is incorporated [37] , expressed 10 times more in SHR than in WKY proximal tubuli [38 -40] . Associated with blood pressure in several F2 crosses [41, 42] . SA gene expression increases before the development of hypertension from 4 weeks of age [43, 44] .
Suggested presence of another QTL after Na loading, 55 cM from the SA locus, around a cluster of cytochromes P450 loci [45] . SS/Jr ϫ Lew ␤ & ␥ Na channel ␤ and ␥ subunits of the epithelial Na channel map close to SA [46] ; suggested linkage with the ␤ subunit [47] . SHR ϫ BN SHR-SP ϫ WKY Kallikrein Kallikrein maps on chromosome 1 and was found linked to hypertension [48] .
Chromosomal region associated with a locus that reduces blood pressure, observed in a congenic SHR strain receiving the chromosomal segment from BN [49] . SHR ϫ BN 10 ACE/GH Strong association between blood pressure and some markers on a region near the ACE gene in several crosses [52, [65] [66] [67] . Although five mutations were found in SHR-SP ACE coding regions, only one changes the amino acid, but the gene product has normal K m and V max [68] . However, the ACE locus seems associated only with ACE activity, not blood pressure (congenic and recombinant strains from SHR and WKY) [69] .
SHR-SP ϫ WKY SS/Jr ϫ MNS
SP-BP1a SP-BP1b A QTL associated with basal blood pressure is located 26 cM from the ACE locus (SP-BP1a) whereas another (SP-BP1b) QTL associated with blood pressure after Na load is much closer to the ACE locus (congenic and recombinant strains from SHR and WKY) [70] . Nos2
Alleles of the inducible nitric oxide synthase gene cosegregate with blood pressure. Nos2 maps 27-32 cM from the ACE locus [71] . SS/Jr ϫ MNS SS/Jr ϫ WKY 13 Renin Cosegregation with blood pressure in different F2 populations [72] [73] [74] [75] [76] . No linkage to kidney renin concentration [77] and no point mutation in the renin gene coding region were found [78] . The chromosomal segment carrying the "hypertensive" renin allele is associated with low renin and low blood pressure [79] ; the opposite was found in rats carrying the "normotensive" renin allele (congenic Dahl rats) [80] . Conclusion: the hypertensive effect of the "hypertensive" renin allele, if any, can be expressed only in conjunction with other alleles in still unknown loci.
A segment of 91.6 cM on chromosome 13 (comprising the renin locus) demonstrated a broad peak of linkage to hypertension. The major peak is 21.7 cM from the renin gene. In this chromosomal region there are at least two other known candidate genes for hypertension or its complications: the cardiac isoform of troponin T (less than 3 cM from the renin gene) and the ␣2 subunit of the Na ϩ ,K ϩ -ATPase gene less than 60 cM away), although the latter did not reach statistical significance for linkage [55] .
SHR ϫ WKY 14
␣-Adducin Missense mutations found in the coding region of ␣-adducin and ␤-adducin (which maps on chromosome 4). Their epistatic interaction explains up to 50% of the blood pressure difference between MNS and MHS rats [81] . The "hypertensive" ␣-adducin variant affects actin assembly, and stimulates the Na ϩ ,K ϩ -ATPase activity in a cell free system and in transfected renal tubular cells [82, 83] .
MHS ϫ MNS 17 MITH Testis-specific histone locus cosegregates significantly with high blood pressure [58] . SS/Jr ϫ Lew 19 AGT The angiotensinogen locus does not seem involved in blood pressure control in rats [84, 85] although tissue-specific angiotensinogen gene expression is different in SHR and WKY [86] . SHR-SP ϫ WKY 20 HSP Heat-shock protein 70 (HSP70) and heat shock protein 27 (HSP27) genes are overexpressed in response to various stresses in rats and are genetically linked to hypertension [87, 88] .
Linkage to the Y chromosome in SHR and SHR-SP [89 -91] , not confirmed in a different SHR stock [92] . The proposed candidate gene is Tty, which affects the timing of testosterone secretion [93] . SHR ϫ WKY SHR-SP ϫ WKY X Sp-BP3 A QTL was found in an F2 population [65] . SHR-SP ϫ WKY Transgenic rats created by microinjection of the mouse renin-2 gene into non-hypertensive non-inbred SpragueDawley rats have fulminant hypertension, low plasma renin, enhanced corticosteroids secretion and several other developmental and regulatory abnormalities [97] . Mice carrying from 0 to 4 functional copies of the murine wild-type angiotensinogen (AGT) gene at its normal chromosomal location have a significant and almost linear increase in blood pressure and serum AGT concentration per gene copy, although the normal compensatory mechanisms are intact [95] . Substantially similar results were obtained in transgenic mice receiving the rat AGT gene [96] . Transgenic mice carrying both the human renin and the human AGT genes under the control of their native promoters have high blood pressure and may be a good model for human high renin hypertension [97] . Disruption of the angiotensin converting enzyme (ACE) gene in mice reduced blood pressure by about 50% and serum ACE activity to zero [98] , whereas when only one functional allele was left blood pressure remained normal, ACE activity was reduced by about 50% and renal renin mRNA increased fourfold [99] . Three functional copies of the ACE gene left blood pressure normal despite a 50% increase of serum ACE activity. These studies indicate that important homeostatic adaptations normalize the blood pressure of mice in spite of changes in ACE gene function, and that only large changes of ACE gene expression affect blood pressure, exceeding the capacity of the homeostatic mechanisms [100] .
Transgenic mice expressing the human tissue kallikrein gene have lower blood pressure than controls [101] . Mice homozygous for atrial natriuretic peptyde (ANF) gene inactivation had hypertension on a normal salt diet whereas heterozygous ones had hypertension only with a high salt diet, demonstrating that genetically reduced production of ANF can lead to salt-sensitive hypertension [102] . The opposite experiment consisted of the production of transgenic mice with a fusion gene composed of mouse transthyretin (TTR) promoter fused to the mouse ANF structural gene. This gene is continuously expressed in the liver and its end effect is a chronic elevation of plasma ANF concentration. The mean arterial blood pressure of transgenic animals harboring the TTR-ANF fusion gene was low and inversely proportional to hepatic ANF expression [103] .
Transgenic mice overexpressing the Na-H exchanger reabsorb more sodium and water and increase their systolic blood pressure after salt loading [104] . Targeting disruption of the angiotensin II type 1A receptor gene reduced the blood pressure by 12 mm Hg in heterozygous mice and by 25 mm Hg in homozygous mice [105] . Disruption of the endothelin 1 (ET1) gene caused death at the birth of homozygotes, whereas heterozygotes (which produced lower levels of ET1 than wild-type mice) became hypertensive [106] . Also, endothelial nitric oxide synthase (eNOS) gene disruption caused hypertension [107] .
Genetic analysis in human hypertension
The mass of available data on experimental animals is overwhelming. Almost all rat chromosomes contain at least one QTL, so interpretation of this "genetic soup" is particularly difficult. There are far fewer positive results in humans, and we propose to analyze the data on the renin-angiotensin system and adducin in detail, as in each case both linkage and association studies were positive and confirmed in different populations. Negative or unconfirmed results for other candidate loci are summarized in Table 2 .
Renin-angiotensin system. (a) Renin locus. No significant difference was found in the distribution of the alleles between hypertensives and normotensives, nor was an excess of alleles detected in affected sib-pairs [134 -136] , although a Japanese casecontrol report found an association with a family history of hypertension [137] . Although these data are not sufficient to definitively exclude the renin locus, they are a strong indication against its involvement in the pathogenesis of human essential hypertension.
(b) Angiotensinogen. Variants of the AGT gene have been studied extensively in humans since the first demonstration [138] of their involvement in human essential hypertension. AGT is the substrate of renin and its plasma level or amino acidic sequence may affect angiotensin I production by a given level of renin. Ten diallelic polymorphisms have been identified in the AGT gene [139] . The M235T polymorphism affects plasma AGT levels, which are lowest in hypertensive individuals homozygous for the M235 variant, intermediate in heterozygous ones and highest in homozygotes for the 235T variant. The latter allele is more frequent in hypertensives than in normotensives. It appears that a mutation in the promoter, 6 bp upstream from the initiation site of transcription, in tight linkage with the M235T variant, is the causal mutation [140] as it affects the basal transcription rate. It is associated with early onset of hypertension [141, 142] . The association between 235T and hypertension has been confirmed in several populations [143, 144] in spite of large differences in allele frequencies [145, 146] . In some Caucasian samples the association was not confirmed but the number of subjects was probably too small [147] [148] [149] . Significant linkage was confirmed in a group of English families [149] and among Afro Caribbeans [150] . The renovascular response to angiotensin II infusion was blunted in hypertensives with the 235T genotype, and this is relevant to the development of hypertension as an intrinsic activation of the kidney reninangiotensin system may be present in these patients [151] .
(c) Angiotensin converting enzyme. A 287 base pair insertion (I)/deletion (D) polymorphism in intron 16 of the gene encoding ACE has been shown to affect its plasma levels [152, 153] and the blood pressure response to infused angiotensin I [154] . This extensively tested polymorphism does not seem directly involved in essential hypertension [155] [156] [157] [158] . The age-related increase in the I allele frequency (associated with low serum ACE) in hypertensives [159, 160] was interpreted as excess mortality in elderly hypertensives carrying the D allele. The D allele is variably associated with complications of hypertension as myocardial infarction or ischemia [161, 162] , ventricular hypertrophy [163, 164] and carotid artery thickness [165] , although two large studies challenged the association of the D allele with ischemic heart disease and myocardial infarction [166, 167] . The negative ACE locus findings conflict somewhat with the positive ones in rats. Very recently a linkage study on a large number of affected sib pairs (518 sib pairs) provided strong evidence of linkage for a marker 18 cM centromeric with respect to the ACE locus on chromosome 17 [168] . This study is important for two reasons: (1) It used a different strategy to locate a susceptibility locus for human essential hypertension. Instead of looking for a pathophysiologically plausible candidate gene, the authors tested a region of a human chromosome that is syntenic to a rat one, already found linked to rat hypertension. (2) The peak of significance found is practically superimposable on the one reported in some families with Gordon's syndrome (Fig. 1) [26] . Gordon's syndrome is treatable with thiazide diuretics. The resemblance to essential hypertension needs further studies.
Adducin. The possible involvement of the ␣-adducin locus on chromosome 4p16.3 in blood pressure control was tested by polymorphic markers mapping at various distances from the locus in a case-control study [169] and in a sib-pair study [170] . Positive results were obtained in both studies. Variants in the ␣-adducin amino acidic sequence were also detected, one of which (Gly460Trp) was associated with essential hypertension [170] . The blood pressure of heterozygous hypertensive patients was more sensitive to changes in sodium balance and the administration of diuretics compared to that of patients homozygous for the more frequent Gly460 variant [170] , and the slope of the pressure natriuresis function was less steep as in cases of hypertension caused by a primary increase in tubular sodium reabsorption [171] . Sodium handling in the rare Try460Try homozygotes seems similar to that in heterozygotes. The association has been confirmed in two case-control studies, one of a Caucasian and one of a Japanese ethnic origin [172, 173] . 
Cusi and Bianchi: Genetics of hypertension
In conclusion, AGT and adducin seem to be the only genes for which at least two association studies and one linkage study yielded positive results in human essential hypertension. However, there are fewer published studies from independent groups of investigators on adducin than on AGT.
Comparison between animal and human results. Only three genes (or loci) have been found positive in humans in different populations compared with the numerous positive results in animals. There are two possible explanations for the discrepancy: (1) The number of genes involved in human essential hypertension is greater than the number responsible for hypertension in individual rat strains. This produces a "dilution" of the effect of a given gene when an unselected population of hypertensive patients is tested for either association and/or linkage. (2) The experimental set-up may influence the results. Studies in rats were performed after more than 20 generations of brother-sister mating (followed, if necessary, by several specific backcrosses). The situation is obviously greatly different in humans, where random mating occurs. Furthermore, the conditions of blood pressure recording in rats have been far from physiological in most of the published experiments (pre-warming and handling of the animal for indirect tail-cuff measurements or insertion of a catheter in a carotid artery and only few hours of recovery after anesthesia). Certainly the genes (or loci) detected in rats all code for (or are linked to genes that code for) proteins whose function is somehow involved in blood pressure regulation. At present it is unknown to what extent the artifacts induced by such stressful protocols amplified the role played by genes that might have provided only a minor contribution to blood pressure control if the animal had been studied in its own natural environment and allowed to mate randomly.
In this light, positive, ambiguous and negative results obtained in humans are all relative terms. As previously noted, it seems likely that the genotype relative risk for human essential hypertension genes detected thus far is very low (for the M235T variant of AGT from different studies, we calculated that for Caucasians it is about 1.5 to 1.6; that of adducin is 1.8 [170] ). According to the calculations of Risch and Merikangas, significance for a sib pair study could be expected only for a much larger sample size than that used in the positive linkage studies published (at least 500 to 600 sib pairs for AGT and 250 to 350 for adducin) [16] . Furthermore, individual research units will rarely be able to collect sufficiently large sample sizes that can reach enough power to yield statistically convincing results. In this regard large collaborative studies such as the recent European study on AGT [174] may be of little use, because marker allele frequencies are likely to vary between different populations. In spite of this difficulty, more stringent criteria are being proposed for declaring positive linkage, as multiple testing may indeed increase the chance of finding false positive results [14] . Though not all authors agree [175] , the problem of false positive results, together with the symmetric one of too weak and hence rejected true positive findings, remains. In a comment specifically about mental illness, which is equally applicable to essential hypertension, Risch wrote that false-negative results may be more damaging to the field than false-positive ones [176] . Is it possible to avoid the risk of false positives by using alternative approaches to investigate the pathogenetic mechanisms of essential hypertension? 
THE FUTURE DIRECTION IS BACK TO PHYSIOLOGY
A reasonable alternative possibility is focusing on linkage (and on linkage dysequilibrium) of very precisely defined candidate genes. They should be tested based on rational hypotheses and solid experimental data showing their pathogenetic importance in causing intermediate phenotypes (for example, salt-sensitivity, pressor response to stress, pressor response to angiotensin, etc.). Linkage of the candidate gene and their epistatic interactions should be sought with both the intermediate phenotype and blood pressure. The solid pathophysiological background of knowledge, supporting the role of the kidney in the control of blood pressure via the modulation of body sodium, fluids and renin, may be used to unravel the genetic causes of human essential hypertension. Certainly other mechanisms are important in blood pressure control. However, in our opinion (or perhaps bias), the mechanisms related to sodium balance and renin rank first in the hierarchical organization of the long-term control of blood pressure. Many experimental demonstrations suggest that the causes of stable hypertension must in some way affect the pressure-natriuresis relationship. For example, a chronic subpressor infusion of angiotensin changes the pressure-natriuresis function in the dog and makes it salt-sensitive [177] . Most of the positive linkage studies in rats and humans indicate some abnormality in the renin-angiotensin system in the direction of increased activity of any of its components (renin, ACE, AGT) [178] , together with some alteration in renal sodium handling. This impressive body of both pathophysiological and genetic data should stimulate efforts to understand the interactions among the genes that control the renin-angiotensin system and renal sodium handling either directly at the tubular level or indirectly through hormones that affect tubular sodium reabsorption. In fact, the most important challenge in the genetics of essential hypertension is how to assess the role of a given gene in humans over the large polygenic and environmental background noise. Certainly all the sophisticated genetic analyses proposed by the statisticians are very helpful. However, we doubt that they will give us the final answer; after all, statistics is only a methodological tool.
Alternatively, we may organize the available knowledge of a complex physiological system like the control of blood pressure in a hierarchical fashion from the most important to the least important mechanism, and the mechanism that must always be involved in the control of the set point of blood pressure regulation should rank first. For instance, comparison of the data on the role of the renal pressurenatriuresis function and its relation with renin in long-term control of blood pressure with the data on the role of the sympathetic nervous system shows that the former ranks before the latter, in our opinion. Therefore, polymorphism of the genes that control the first mechanisms should always be assessed in any population study. Studies of the role of polymorphism of other genes controlling other mechanisms may be integrated. It is crucial to know the number of subjects needed to ensure the proper power to the study. According to Risch and Merikangas' above-mentioned calculation the number of sib pairs needed to assess the effect of minor genes in linkage studies, we should estimate the optimum size of a given population sample to ensure enough power for the study of a given number of genes with their epistatic interactions. The large sample size required may be prohibitive, and therefore efforts should be made on the one hand to select the most pathophysiologically meaningful gene polymorphism, and on the other to set up the appropriate statistical tools or new computational approaches [18] .
Following this line of thought, as an example of our experimental and possibly theoretically biased approach to these problems, we briefly summarize our study of adducin as a paradigm.
ADDUCIN AS PARADIGM FOR THE SEARCH FOR GENETIC MECHANISMS OF ESSENTIAL HYPERTENSION
Adducin was identified as a candidate gene after a long series of comparisons between MHS and MNS rats at different levels of biological organization [reviewed in 179] . Such studies demonstrated that the development of hypertension in MHS is accompanied by renal sodium retention, normalization of a higher glomerular filtration rate and a relative increase of a lower plasma renin activity (compared to MNS of the same age). These experimental results, together with the possibility of "transplanting" hypertension with a kidney transplant, led to the hypothesis that hypertension in MHS was caused by a genetically determined increase of renal tubular reabsorption of sodium. The higher glomerular filtration rate was also confirmed in MHS isolated kidney preparations in which increased tubular sodium reabsorption was also observed. Sodium transport was also faster in isolated tubuli and in isolated luminal and basolateral membranes from MHS. As a similar increase of sodium transport rate was also detected on the erythrocyte membrane, the latter were used to identify the underlying molecular mechanism. In erythrocytes the faster sodium transport was genetically determined and genetically associated with higher blood pressure values in segregating the F2 (MHS x MNS) populations. As the faster erythrocyte transmembrane sodium transport could be normalized by removal of the membrane skeleton proteins, we hypothesized that one of the membrane skeleton proteins could play a role in the faster sodium transport rate of the MHS. Then, with cross-immunization of membrane cytoskeleton proteins, we found that adducin was different in MHS and MNS. Sequencing MHS and MNS ␣ and ␤ subunits of adducin led to the identification of the already mentioned variants that interact epistatically in determining the blood pressure difference between MHS and MNS [81] . Complementary DNA transfection of MHS or MNS adducin as well as incubation of the MHS or MNS adducin variant with purified Na ϩ ,K ϩ -ATPase (the enzyme that produces the driving force for tubular sodium reabsorption) demonstrated that MHS ␣ adducin stimulates the Na pump at a much lower concentration than MNS ␣ adducin [82, 83] .
Also, in humans case control studies in three independent cohorts [170, 172, 173] and one linkage study [170] confirmed the involvement of adducin polymorphism in essential hypertension. In particular, hypertensive patients carrying the hypertensive variant were more sensitive to changes in body sodium than patients carrying the wild-type variant. This finding strongly supports the notion that the "hypertensive" ␣ adducin allele has a role in the control of tubular reabsorption of sodium and blood pressure in both MHS rats and hypertensive humans. The very high amino acid homology (ϳ94%) between human and rat adducin suggests that the same biological role is played in the two species, and that even small changes in the amino acid sequence can affect its biological function. However, the mutation is not the same in rats and humans, and so far only the rat variants have been transfected in tubular cells and studied in a cell-free system with isolated renal Na ϩ ,K ϩ -ATPase. The same studies also should be carried out on the human variant to assess the similarities between humans and rats at the molecular level.
